重组链激酶与尿激酶溶栓治疗AMI疗效研究

The Study of Refom Streptokinase and Urokinase Therapy Effect to Acute Miocardial Infarction

目的：为选择临床应用有效安全的溶栓剂。方 法：筛选了５６例急性心肌梗塞（ＡＭＩ）患者，按治疗时间先后，随机分两组，分别应用国产重 组链激酶（ｒ－ＳＫ）和合资华泰尿激酶（ＵＫ）行静脉溶栓治疗。观察其疗效及副作用。根据临床冠 脉再通间接指征［１］判断再通率。结果：再通率ｒ－ＳＫ组为７２．４％（２１／２９），ＵＫ组为５１．．９％（１４／２７）。两组比较差异有显著性（Ｐ＜０．０５）。副作用，ｒ－ＳＫ发热寒战 率１０．３％，低血压发生率３．５％，上消化道出血１０．３％；ＵＫ无寒战发热和低血压，上消化道 出血７．４％。两组均未发生脑出血及其他部位严重出血。结论：ｒ－ＳＫ静脉溶栓治疗ＡＭＩ效果优 于ＵＫ。

Objective:To choose drugs of dissol ving embolus,it is efficiency and safe in clinic.Methods:56 patients with acute miocardial infarction(AMI)were divided into two groups randomly:the group treate d with reformstreptokinase(r-SK) maded in china and the group treated with huaTa i urokinase(UK).The again opening quotietyof dissolving embolus were estimate wi th clinic coronary again opening point sign.Results:The again opening quotiety:I t were 72.4% in the r-SK group,It were 51.9% in the UK group.The again opening q uotiety were higher in the r-SK group than in the UK group (P＜0.05).T he side effect:The fever and chill quotiety of the r-SK group were 10.3%;the ari sing quotiety of low blood pressure were 3.5% in the r-SK group;The superior ent eron hemorrhage were 10.3% in the r-SK group.The fever,chill and low blood press ure had not happened in the UK group,but the superior enteron bleeding were 7.4% in the that.The cerebral hemorrhage and else part hemorrhage had not happened.Conclution:The effect of dissolving embolus were higher in r-SK group than in UK group.